Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional-dose pneumococcal conjugate vaccine study in Kenyan infants
PACTR202104717648755Phase 4Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jul 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Prevnar 13 and pneumococcal conjugate vaccine in pneumococcal disease (4 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: Non-inferior immunogenicity at 1 month post-boost. Started Jul 2018; status: completed.
02
Drugs
Prevnar 13pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on PACTR202104717648755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104717648755.